GTCR to support Zentiva's next phase of growth, building on its strong foundation of quality, scale and market leadership

CHICAGO and PRAGUE, April 9, 2026 /PRNewswire/ -- GTCR, a leading private equity firm, announced today that it has closed the previously announced acquisition of Zentiva (the "Company"), a leading European generics pharmaceutical company, from Advent, a leading global private equity investor.

Zentiva is focused on the development, manufacturing and supply of generic, branded specialty and over-the-counter medicines and products, serving more than 100 million people across over 40 countries. The Company is supported by established R&D capabilities and a deep commitment to clinical excellence and product quality across its portfolio.

GTCR will partner with Zentiva's management team, led by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to support the Company's next phase of growth. GTCR has longstanding relationships with both Mr. Saltofte and Mr. Murphy, both seasoned leaders with proven track records at various healthcare businesses, including at Acino and GE HealthCare.

GTCR has a long history of investing in healthcare over the past 45 years, including in the pharmaceutical sector. The firm will support Zentiva's next phase of growth through continued investment in new product development, portfolio breadth, and geographic reach, with a focus on improving patient access to essential medicines and supporting sustainable healthcare systems.

"We are proud of Zentiva's strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth," said Steffen Saltofte, CEO of Zentiva. "With GTCR's support and significant industry expertise, we believe we are ideally placed to accelerate our momentum and continue our mission of expanding access to high-quality, affordable medicines to millions of people across Europe."

"We are excited to partner with Steffen and the Zentiva team to further the Company's success," said Sean Cunningham, Managing Director and Head of Healthcare at GTCR. "As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long-term growth and impact."

Tom Allen, Managing Director at Advent, added, "We are immensely proud of the business Zentiva has become during our partnership — a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines. We would like to thank Steffen and all the talented Zentiva team members who played a part in the company's transformation. We look forward to watching Zentiva go from strength to strength in the years ahead."

GTCR was advised by Barclays Bank PLC, acting through its Investment Bank, and BNP Paribas as lead financial advisors, Morgan Stanley & Co. LLC as a financial advisor, and Kirkland & Ellis LLP as legal advisor.

Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors and Freshfields as lead legal advisor.

About GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Zentiva

Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded together by a commitment to the people who depend on our products every day. Visit us at www.zentiva.com

About Advent

Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $100 billion in assets under management* and have made 448 investments across 44 countries.

Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.

As one of the largest privately-owned partnerships, our 655 colleagues leverage the full ecosystem of Advent's global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.

To learn more, visit our website or connect with us on LinkedIn.

*Assets under management (AUM) as of September 30, 2025. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles.

Media Contacts

GTCR Media Contact

Josh Clarkson / Ryan Smith / Peter Gavaris

Pro-GTCR@Prosek.com 

Zentiva Media Contact

Marie-Claire Rees

Head of Communications, Zentiva

media@zentiva.com

Advent Media Contact

Peter Folland

Vice President, Communications, Advent

pfolland@adventinternational.co.uk

Logo - https://mma.prnewswire.com/media/2624007/GTCR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/gtcr-completes-acquisition-of-zentiva-a-leading-european-generics-pharmaceutical-company-302737491.html

Der frühere SP-Nationalrat und langjährige Preisüberwacher Rudolf Strahm geht mit seiner Partei in der Migrationspolitik ungewohnt scharf ins Gericht. Ausgelöst wird die jüngste Auseinandersetzung durch die sogenannte 10-Millionen-Schweiz-Initiative der SVP, über die im Juni abgestimmt wird. Strahm teilt zwar die offizielle Ablehnung der Vorlage durch die SP, kritisiert jedoch den Umgang damit als planlos und taktisch ungeschickt. Die Partei habe «kein Konzept», wie sie der Initiative begegnen solle, und beschränke sich auf ein «blankes Nein», sagte er in mehreren Interviews.

Besonders stört Strahm, dass die Sozialdemokraten ihre Ablehnung nicht an konkrete Bedingungen geknüpft haben. Aus seiner Sicht hätte die SP die Gelegenheit nutzen müssen, um Massnahmen gegen Wohnungsnot, zur besseren beruflichen Integration von Migranten oder zur Bekämpfung des Fachkräftemangels in der Pflege durchzusetzen. Stattdessen verlaufe der Abstimmungskampf mit «populistischer Rhetorik» und «rhetorischen Tiefflügen», ohne dass tragfähige Lösungen präsentiert würden. Damit politisiere die Partei «am Volk vorbei» und ignoriere die Sorgen weiter Teile der Bevölkerung, auch weit ins linke Lager hinein, die sich wegen der hohen Zuwanderung mindestens besorgt zeigten.

Strahm verknüpft seine Kritik eng mit den sozialen Folgen der starken Zuwanderung. Die hohen Nettozuzüge überforderten die Gesellschaft und verschärften Probleme auf dem Wohnungsmarkt sowie bei den Lebenshaltungskosten. Nach seiner Analyse haben insbesondere die unteren 20 bis 40 Prozent der Bevölkerung in den vergangenen zehn Jahren an Kaufkraft verloren, weil Mieten, Krankenkassenprämien und Verkehrskosten deutlich stärker gestiegen seien als die allgemeine Teuerung. Dies hänge «auch mit der Zuwanderung zusammen». Wer Wachstum nur über das Bruttoinlandprodukt messe, betreibe «Vulgärökonomie», so Strahm; entscheidend sei das Wachstum pro Kopf und dessen Verteilung.

Die SP, einst klar als Partei der Arbeiterschaft positioniert, verfehle es laut Strahm, diese sozialen Spannungen offen zu thematisieren. Sie schweige zu den Ängsten und verdränge die Auswirkungen der Zuwanderung auf Wohnen, Löhne und Alltagskosten. Damit überlasse sie die entsprechenden Fragen der SVP. Strahm geht so weit zu sagen, heute sei nicht mehr die SP, sondern die SVP die Partei der Arbeiter – nicht, weil diese besonders viel für die unteren Einkommensschichten tue, sondern weil sie ihnen eine Identität anbiete. Die jüngste Kritik fügt sich ein in eine längere Reihe von Differenzen zwischen Strahm und der Parteilinie in europäischer Integrations- und Migrationspolitik, die ihn seit den 1990er-Jahren zu einem der profiliertesten internen Widersacher der offiziellen SP-Positionen auf diesem Feld gemacht haben.